The review found no eligible studies for this question.
It is very uncertain whether chemoradiotherapy changes recurrence compared with radical surgery (very low certainty).
The review found no eligible studies for this question.
Extended‐field radiotherapy probably leads to lower overall survival compared with pelvic radiotherapy (moderate certainty).
Extended‐field radiotherapy probably leads to lower para‐aortic lymph node recurrence compared with pelvic radiotherapy (moderate certainty).
Extended‐field radiotherapy showed no clear difference in progression‐free survival compared with pelvic radiotherapy (moderate certainty).
Extended‐field radiotherapy showed no clear difference in adverse events compared with pelvic radiotherapy (moderate certainty).
Extended‐field radiotherapy probably leads to lower overall survival compared with pelvic chemoradiotherapy (moderate certainty).
Extended‐field radiotherapy may leads to lower para‐aortic lymph node recurrence compared with pelvic chemoradiotherapy (low certainty).
Extended‐field radiotherapy probably leads to lower progression‐free survival compared with pelvic chemoradiotherapy (moderate certainty).
Extended‐field radiotherapy probably leads to lower acute adverse events compared with pelvic chemoradiotherapy (moderate certainty).
Extended‐field radiotherapy showed no clear difference in late adverse events compared with pelvic chemoradiotherapy (moderate certainty).
It is very uncertain whether extended‐field chemoradiotherapy changes overall survival compared with pelvic chemoradiotherapy (very low certainty).
It is very uncertain whether extended‐field chemoradiotherapy changes para‐aortic lymph node recurrence compared with pelvic chemoradiotherapy (very low certainty).
It is very uncertain whether extended‐field chemoradiotherapy changes progression‐free survival compared with pelvic chemoradiotherapy (very low certainty).
It is very uncertain whether extended‐field chemoradiotherapy changes acute adverse events compared with pelvic chemoradiotherapy (very low certainty).
It is very uncertain whether extended‐field chemoradiotherapy changes late adverse events compared with pelvic chemoradiotherapy (very low certainty).
It is very uncertain whether hypofractionated radiotherapy changes overall survival compared with daily conventionally fractionated radiotherapy (very low certainty).